Pantoja-Villagómez D

Idioma: Español
Referencias bibliográficas: 37
Paginas: 507-513
Archivo PDF: 229.82 Kb.

RESUMEN

Introducción: La esquizofrenia es un desorden mental crónico y degenerativo. Existe evidencia de neuroinflamación en la esquizofrenia. El A9-THC modula el equilibrio Th-1/Th-2 e inhibe la producción de citocinas, quimosinas y la migración de células inflamatorias. Objetivo: Evaluar y comparar la respuesta inmunológica de pacientes con esquizofrenia con y sin consumo de Cannabis mediante las escalas PANSS, FACT-Sz y poblaciones linfocitarias. Material y métodos: Pacientes que acudieron al INPRFM de abril a noviembre de 2016. La muestra se conformó con 23 pacientes con esquizofrenia divididos en aquellos con y sin consumo de Cannabis. Resultados: La edad promedio fue 33.7 años. El 100% fueron solteros, en tratamiento con risperidona u olanzapina, con una media de tratamiento de 26.96 semanas, con una dosis media de 145.65 mg equivalentes de clorpromazina, una media de 18.26 hrs desde su último consumo, tiempo total de consumo: 169.57 semanas. Los pacientes obtuvieron una media en la escala PANSS total de 103.4 y un FACT-Sz de 65.2, sin diferencias significativas. En el recuento linfocitario se observaron diferencias significativas en los linfocitos T CD3+CD8+ y células NK. Conclusiones: Los pacientes presentan una disminución en los linfocitos T CD4+CD8+ y un aumento en las células NK; es habitual el consumo de otras sustancias, comorbilidades psiquiátricas y médicas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res. 2010; 121 (1-3): 46-54.

2. American Psychiatric Association. Guía de consulta de los Criterios Diagnósticos Del DSM-5. American Psychiatric Association; 2014. p. 267.

3. Lieberman JA, Stroup S, Perkins DO. The American Psychiatric Publishing Textbook Of Schizophrenia. 2006. p. 453.

4. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994; 89 (5): 346-351.

5. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011; 70 (7): 663-671.

6. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Progress Neuropsychopharmacol Biol Psychiatry. 2013; 42: 115-121.

7. Suárez-Pinilla P, López-Gil J, Crespo-Facorro B. Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun. 2014; 40: 269-282.

8. Pandey GN, Ren X, Rizavi HS, Zhang H. Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res. 2015; 164 (1-3): 193-198.

9. De Filippis D, D’Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008; 20 (1): 20-25.

10. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006; 20 (6): 532-545.

11. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Muller N. T-and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 2007; 152 (2-3): 173-180.

12. Ueda Y, Miyagawa N, Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci. 2007; 80 (5): 414-419.

13. Cunha JM, Carlini EA, Pereira E, Ramos OL, Pimentel C, Gagliardi R et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980; 21 (3): 175-185.

14. D’Souza DC. Cannabinoids and psychosis. EUA: Department of Psychiatry, Yale University School of Medicine; 2016.

15. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004; 25 (1-2): 14-23.

16. Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016; 15 (6): 513-528. doi: 10.1016/j.autrev.2016.02.008

17. Klein TW, Newton WC, Zhu Daaka YH, Friedman. Delta 9-tetrahidrocannabinol, citoquinas y la inmunidad a Legionella pneumophila. Proc Soc Exp Biol Med. 1995; 209 (3): 205-212.

18. Watzl B, Scuderi P, Watson RR. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol. 1991; 288: 63-70.

19. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipidos. 2000; 108: 169-90.

20. Franco R, Pacheco R, Lluis C, Ahern GP, O’Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol. 2007; 28 (9): 400-407.

21. Kumar RN. Cámaras WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001; 56 (11): 1059-1068.

22. Lee CY, Wey SP, Liao MH, Hsu WL, Wu HY, Jan TR. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol. 2008; 8 (5) 732-740.

23. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Movement disorders. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Haworth Press. 2002, pp. 205-214.

24. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005; (168): 1-51.

25. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74 (2): 129-180.

26. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mastcells. J Immunol. 2003; 170 (10): 4953-4962.

27. Sexton M, Silvestroni A, Möller T, Stella N. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology. 2013; 21 (3): 253-259.

28. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther. 1998; 285 (1): 285-292.

29. Howlett C, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002; 54 (2): 161-202.

30. Lee SF, Newton C, Widen R, Friedman H, Klein TW. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cells stimulation. Eur J Pharmacol. 2001; 423 (2-3): 235-241.

31. Maccarrone M, Lorenzon T, Bari MG, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000; 275 (41): 31938-31945.

32. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365 (6441): 61-65.

33. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta (9)-apoptosis tetrahidrocannabinol inducida en el timo y el bazo como un mecanismo de inmunosupresión in vitro e in vivo. J Pharmacol Exp Ther. 2002b: 302 (2): 451-465.

34. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Corazón Circ Physiol. 2008; 294 (3): H1145-H1155.

35. Small-Howard MA, Shimoda LM, Adra CN, Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. J Biochemical J. 2005; 388 (2): 465-473.

36. Cabral GA, Staab A. Effects on the immune system. Handb Exp Pharmacol. 2005; (168): 385-423.

37. Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A et al. Novel rating scales for schizophrenia Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res. 2008; 106 (2-3): 328-336.